Medically reviewed by Brian Bezack, DO Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive pulmonary disease (COPD). Aside from the fact that they are ineffective for ...
New GOLD guidelines recommend using pre-bronchodilator spirometry to rule out COPD and post-bronchodilator measurements to ...
The main goals of chronic obstructive pulmonary disease (COPD) management include treatment of symptoms and prevention of exacerbations. Current guidelines recommend use of one or more long-acting ...
Due to the destructive nature of COPD on patients’ lungs and well-being, timely diagnosis is key, and integrating spirometry ...
The drug has a marketing authorisation in a pressurised metered-dose inhaler (pMDI), as a maintenance dual bronchodilator to relieve symptoms in adults with COPD.
The current pathophysiology of COPD encompasses three main characteristics: emphysema, chronic bronchitis and small airway disease. Macrophages and neutrophils are implicated in this process; thus ...
The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...